Vol. 23/No. 17

For clinicians tasked with treating patients with prostate cancer, disease visualization has traditionally consisted of imprecise techniques such as MRI. However, a new artificial intelligence-based approach by Avenda Health is poised to potentially revolutionize the treatment landscape in the field.

Paul Bunn, MD, elaborates on carcinoembryonic antigen–related cell adhesion molecule 5 as a potential target in the treatment of non–small cell lung cancer.

A panel of hematology cancer experts discuss the current treatment landscape and novel emerging therapies for patients with myelofibrosis.

DNA damage homologous recombination repair genotypic variants are not created equal.

A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.